Endocyte Inc., (http://www.endocyte.com/) a cancer drug discovery and development company, has announced results from a Phase II clinical study of EC145 (http://www.endocyte.com/pipeline.html) in patients with advanced non-small cell lung cancer (NSCLC). Results were presented at the 13th World Conference on Lung Cancer in San Francisco.